Breast CancerColo-rectal CancerOvarian CancerMelanoma (Skin Cancer)Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung)
Study summary
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the disease. It starts with risk prediction and leads to early diagnosis of the disease or recurrence in the subclinical phase.
The PRO-ACTIVE study includes the following activities:
* WP1: Integrated DNA-RNA approach for the identification of hereditary markers of predisposition to tumors
* WP2: Global biological and molecular analysis of the host and tumor for the prevention and monitoring of recurrences
* WP3: Analysis of the immunological status for the diagnosis of primary prevention and relapses in correlation to genetic and environmental factors
* WP4: Study of the tumor microenvironment for recurrence prediction
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age \>18 years;
* Patients with breast cancer, including patients who meet the AIOM criteria for eligibility for BRCA testing and patients with lobular breast cancer;
* Patients with radically resected colon cancer, including patients with stage III colon cancer and vascular invasion;
* Patients with ovarian carcinomas;
* Patients with metastatic melanoma;
* Patients with stage IIB and IIIA non-small cell lung cancer.
Exclusion Criteria:
* Age \<18 years;
* Unwillingness or inability to give informed consent
Primary outcome measure(s)
Number, frequency and type of genetic variants in known genes not detected by routine diagnostic tests for hereditary tumours — From enrollment to the last clinical follow-up at month 12 Patients will undergo blood sampling for the extraction of nucleic acids (DNA and RNA) to determine number, frequency and type of genetic variants in known genes not detected by routine diagnostic tests for hereditary tumours
Trial sites (1)
Facility
City
Region
Status
Fondazione del Piemonte per l'Oncologia-IRCCS Candiolo
Candiolo
Turin
Recruiting
More Fondazione del Piemonte per l'Oncologia trials in Italy
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
